127 related articles for article (PubMed ID: 36541130)
1. Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients.
Fukushi Y; Akamine Y; Abumiya M; Tozawa N; Yamashita T; Nara M; Kameoka Y; Takahashi N; Miura M
Br J Clin Pharmacol; 2023 May; 89(5):1695-1700. PubMed ID: 36541130
[TBL] [Abstract][Full Text] [Related]
2. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.
Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB
Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085
[TBL] [Abstract][Full Text] [Related]
3. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia.
Erdélyi DJ; Kámory E; Zalka A; Semsei AF; Csókay B; Andrikovics H; Tordai A; Borgulya G; Magyarosy E; Galántai I; Fekete G; Falus A; Szalai C; Kovács GT
Cell Immunol; 2006 Dec; 244(2):121-4. PubMed ID: 17434155
[TBL] [Abstract][Full Text] [Related]
4. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
Li M; Kong XY; Wang SM
Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
[TBL] [Abstract][Full Text] [Related]
5. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
[TBL] [Abstract][Full Text] [Related]
6. Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females.
Rahikainen AL; Palo JU; Haukka J; Sajantila A
Pharmacogenet Genomics; 2018 Apr; 28(4):99-106. PubMed ID: 29481489
[TBL] [Abstract][Full Text] [Related]
7. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
[TBL] [Abstract][Full Text] [Related]
8. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
Lal S; Wong ZW; Sandanaraj E; Xiang X; Ang PC; Lee EJ; Chowbay B
Cancer Sci; 2008 Apr; 99(4):816-23. PubMed ID: 18377430
[TBL] [Abstract][Full Text] [Related]
9. Influence of ABCB1 (1236C > T, 2677G > T and 3435C > T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line.
Tan DQ
Xenobiotica; 2020 Mar; 50(3):346-353. PubMed ID: 31023123
[TBL] [Abstract][Full Text] [Related]
10. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
[TBL] [Abstract][Full Text] [Related]
12. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.
Sennesael AL; Panin N; Vancraeynest C; Pochet L; Spinewine A; Haufroid V; Elens L
Sci Rep; 2018 Jul; 8(1):10514. PubMed ID: 30002384
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
Erdilyi DJ; Kámory E; Csókay B; Andrikovics H; Tordai A; Kiss C; Filni-Semsei A; Janszky I; Zalka A; Fekete G; Falus A; Kovács GT; Szalai C
Pharmacogenomics J; 2008 Oct; 8(5):321-7. PubMed ID: 17938643
[TBL] [Abstract][Full Text] [Related]
14. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
[TBL] [Abstract][Full Text] [Related]
15. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
[TBL] [Abstract][Full Text] [Related]
16. Effects of
Maeda A; Ando H; Irie K; Hashimoto N; Morishige JI; Fukushima S; Ebi H; Uchida K; Iwata H; Sawaki M
Anticancer Res; 2023 Mar; 43(3):1283-1289. PubMed ID: 36854511
[TBL] [Abstract][Full Text] [Related]
17. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.
Hawwa AF; McKiernan PJ; Shields M; Millership JS; Collier PS; McElnay JC
Br J Clin Pharmacol; 2009 Sep; 68(3):413-21. PubMed ID: 19740399
[TBL] [Abstract][Full Text] [Related]
18. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
[TBL] [Abstract][Full Text] [Related]
19. Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines.
Stillemans G; Djokoto HP; Delongie KA; El-Hamdaoui H; Panin N; Haufroid V; Elens L
Sci Rep; 2021 Apr; 11(1):9000. PubMed ID: 33903659
[TBL] [Abstract][Full Text] [Related]
20. Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.
Maeda A; Ando H; Irie K; Hashimoto N; Morishige JI; Fukushima S; Okada A; Ebi H; Matsuzaki M; Iwata H; Sawaki M
Eur J Clin Pharmacol; 2022 Aug; 78(8):1239-1247. PubMed ID: 35527301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
